hVIVO engages in major phase 2b influeness drug study as exclusive UK clinical site
hVIVO plc (AIM & Euronext: HVO), a rapidly expanding specialist contract research organisation (CRO) renowned for its expertise in human challenge clinical trials for infectious ... Read More
Charles River Laboratories to acquire MPI Research for $800m
In a strategic move to bolster its position in the pharmaceutical research sector, Charles River Laboratories International, Inc. has agreed to acquire Michigan-based non-clinical contract ... Read More